Another original new drug of Hengrui has entered the clinic, and netizens are optimistic about it

On November 21, Hengrui group issued the notice on obtaining the notice of clinical trial, saying that the company recently received the notice of clinical trial approved and issued by the State Drug Administration (hereinafter referred to as "the State Drug Administration") for injection, agreeing to approve the product to carry out clinical trial The drug is a humanized monoclonal antibody independently developed and produced by our company, which can activate and promote the response of anti-tumor T cells, play the role of anti-tumor, and be used for the treatment of advanced malignant tumors with standard treatment failure Secondly, an important message was pointed out in the announcement: after inquiry, there are no similar products on the market or sales data at home and abroad There are mgd-013, relatlimab and other products in the clinical trial stage abroad, and ibi-110, lbl-007 and other products in the clinical trial stage in China Up to now, the R & D cost of the product project has been about 16.66 million yuan Netizen A: "the average development time of a drug from clinical phase 1 to the end of R & D has increased by 26% in the past 10 years, and 6 months in 2018, reaching 12.5 years In 2018, the overall success rate from clinical phase 1 trials to regulatory submission (based on the percentage of successful drug development to the next phase) fell to 11.4% " Forbes magazine also pointed out that 95% of new drugs developed by US pharmaceutical companies failed to go on the market Netizen B: take Alzheimer's disease, which is difficult to develop, as an example The difficulty of new drug development is frightening Many well-known pharmaceutical companies are frustrated Entering the clinic does not necessarily mean success, but it is the beginning of suffering! In January 2018, Takeda pharmaceutical announced the failure of phase III clinical trial of pioglitazone in Alzheimer's disease; Pfizer announced to give up the research and development of Alzheimer's disease; the experimental drug of idalopirdine from lundbeck, a Danish pharmaceutical company, failed to prevent the cognitive decline of patients with mild and moderate Alzheimer's disease, which was once regarded as one of the most promising drugs for Alzheimer's disease treatment In February 2018, MSD announced to stop the clinical trial of verubecestat; in June 2018, the phase III clinical trial of lanabecestat jointly developed by Lilly and AstraZeneca was suspended; in January 2019, Roche announced that the phase III clinical trial of crenezumab failed Netizen C: Although the success rate of new drugs is indeed less than 10%, why do some enterprises still drill into them? It's because once they succeed, the rate of return is more than 1000 times! I believe in Hengrui I'm optimistic about the R & D strength! (all of the above comments are from the self-criticism of netizens and the paraphrase of yaozhi.com) It can be seen that the prospect of new drug R & D is indeed recognized by the public, but its R & D risks do exist In this announcement of Hengrui, most of them actually said that they are relatively optimistic Perhaps this comes from the image of "China's first drug R & D enterprise" created by Hengrui in the people's mind all the time, and also from people's trust in Hengrui's R & D strength Penicillin is the integrated content of yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.